Synageva BioPharma — Trimeris — Merger or Acquisition (July 2011)
32 slides from Synageva BioPharma's merger presentation, Jul 20, 2011
Slide 1: Company Presentation July 2011
© Copyright 2011 Synageva BioPharma™ Company Presentation July 2011 Company Presentation July 2011
Slide 2: Forward-Looking Statements
2 © Copyright 2011 Synageva BioPharma™ Forward-Looking Statements These materials and oral statements made from time to time by Synageva representatives in respect of the same subject matter may contain “forward-looking statements.” These statements can be identified by introductory words such as “e
Slide 3: Synageva Strategy & Direction
Vehicle Focus 3 © Copyright 2011 Synageva BioPharma™ Count- Down Vehicle Focus Synageva Strategy & Direction
Slide 4: Synageva Transaction
4 © Copyright 2011 Synageva BioPharma™ Synageva Transaction Deal Synageva and Trimeris merge in all-stock transaction 3:1 exchange ratio Transaction has been unanimously approved by both boards Rationale Provides Synageva financial resources to aggressively pursue corporate strategy Gives Synageva a
Slide 5: Synageva Investment Highlights
Synageva Investment Highlights 5 © Copyright 2011 Synageva BioPharma™ Rare Disease Experience Unmet Medical Need ERT for LSD – Model is Predictive Patient Dosing Commenced Pull-through Expertise Robust, Efficient and Scalable Team Rare Disease Experience Rare Disease Unmet Medical Need Lead Product
Slide 6: Proven Management Team
Sanj K. Patel Anthony Quinn Eric Grinstead Joe DeCourcey Christine Maurer Carsten Boess 6 Tara O’Meara © Copyright 2011 Synageva BioPharma™ Proven Management Team Chief Executive Officer Sanj K. Patel Chief Medical Officer Anthony Quinn Commercial Operations Eric Grinstead Manufacturing Joe DeCource
Slide 7: Synageva Pipeline
7 © Copyright 2011 Synageva BioPharma™ Program Therapeutic Disease Development Status Regulatory Opportunity Synageva Pipeline SBC-102 (rhLAL) SBC-103 (rhNAGLU) SBC-104 SBC-105 SBC-106 Recombinant Lysosomal Acid Lipase Recombinant a - N - acetyl - glucosaminidase Extra Cellular Protein Enzyme Replac
Slide 8: Lead Program ERT for Lysosomal Acid Lipase Deficiency
Lead Program 8 © Copyright 2011 Synageva BioPharma™ ERT for Lysosomal Acid Lipase Deficiency
Slide 9: SBC-102 Lysosomal Acid Lipase (LAL) Biology
SBC-102 Lysosomal Acid Lipase (LAL) Biology 9 © Copyright 2011 Synageva BioPharma™ Liver lipid content in model of LAL Deficiency Cholesterol esters & TG FFA Free Cholesterol Free cholesterol and fatty acids are key regulators of lipid synthesis LDL LDL receptors lysosome coated vesicle ENDOCYTOSIS
Slide 10: SBC-102 Late Onset LAL Deficiency (CESD)
10 © Copyright 2011 Synageva BioPharma™ SBC-102 Late Onset LAL Deficiency (CESD) Shortened lifespan and morbidity Prominent hepatic manifestations – Fatty liver – Elevated transaminases – Fibrosis – Liver failure Other manifestations: splenomegaly, type II hyperlipidemia Rare disease in a common phe
Slide 11: SBC-102 Early Onset LAL Deficiency (Wolman)
© Copyright 2011 Synageva BioPharma™ 11 SBC-102 Early Onset LAL Deficiency (Wolman) Prominent hepatic and GI manifestations – Hepatomegaly and liver failure – Splenomegaly – Persistent vomiting – Abdominal distension – Profound growth failure Adrenal calcification Rapidly progressive and fatal 4.4 6
Slide 12: SBC-102 Targeting and Activity
12 © Copyright 2011 Synageva BioPharma™ SBC-102 Targeting and Activity Terminal mannose/GlcNac and mannose-6-phosphate (M6P) for targeted delivery Uptake into key cells, including macrophages* Lysosomal localization demonstrated Corrects enzyme deficiency Lysotracker red Overlap images Oregon green-
Slide 13: SBC-102 Corrects Key Disease Related Abnormalities
13 Untreated © Copyright 2011 Synageva BioPharma™ SBC-102 Corrects Key Disease Related Abnormalities Normal 4 weeks 8 weeks Normalizes liver LAL Deficient
Slide 14: SBC-102 Rapid Correction of Growth Failure in LAL Model
14 © Copyright 2011 Synageva BioPharma™ SBC-102 Rapid Correction of Growth Failure in LAL Model Normal LAL Deficient SBC-102 Treated, qw
Slide 15: SBC-102 Efficacy With Every Other Week Dosing
© Copyright 2011 Synageva BioPharma™ 15 SBC-102 Efficacy With Every Other Week Dosing Liver Spleen Marked Reduction In Liver Cholesteryl Ester Content Across A Broad Range Of Doses LAL Deficient Normal
Slide 16: SBC-102 ERT Models Predict Efficacy and Dose
Therapy Pre-Clinical Effective Dose Approved Dose Disease Model Key Results Frequency mg/kg 16 © Copyright 2011 Synageva BioPharma™ SBC-102 ERT Models Predict Efficacy and Dose Aldurazyme 0.5-2mg/kg once weekly (canine) QW 0.58 Lysosomal targeting & substrate reduction Fabrazyme 0.3-3mg/kg twice mon
Slide 17: SBC-102 Clinical Development
17 © Copyright 2011 Synageva BioPharma™ COMMERCIALIZATION Conventional Development Programs SBC-102 Clinical Development Proof of concept established in disease model Small patient numbers accelerate development timelines (~5 years vs 5-10 years for common diseases) Patient dosing initiated within 3
Slide 18: SBC-102 Clinical Development Late Onset (CESD)
18 Phase I/II Open-Label Randomized, Double-Blind, Placebo-controlled Trial © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical Development Late Onset (CESD) Adult patients with liver dysfunction due to LAL Deficiency Open label dose escalation 4 week dosing 3 dose levels Multicenter N = 9 Patient
Slide 19: SBC-102 Clinical Development Early Onset (Wolman)
19 Phase I/II Open-Label Open-Label Long-term Extension © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical Development Early Onset (Wolman) Growth failure in children due to LAL Deficiency Open label dose escalation 4 month dosing Multicenter N= 8 Active Phase I/II Open-Label Primary endpoint: Sa
Slide 20: SBC-102 Clinical and Regulatory Milestones
20 © Copyright 2011 Synageva BioPharma™ SBC-102 Clinical and Regulatory Milestones IND filed on schedule and cleared within 30 days EU CTAs filed 3 months ahead of schedule US & EU orphan drug designations granted 2010 Proof of concept data presented at key meetings Clinical production for studies o
Slide 21: SBC-102 Compassionate Use: Patient Data
© Copyright 2011 Synageva BioPharma™ 21 SBC-102 Compassionate Use: Patient Data An infant with LAL Deficiency has received treatment with SBC-102 on a compassionate use basis – Presented with anemia, increasingly abnormal liver function tests, and growth failure prior to treatment – Child has receiv
Slide 22: ERT for MPS IIIB / Sanfilippo B SBC-103 (rhNAGLU)
22 © Copyright 2011 Synageva BioPharma™ ERT for MPS IIIB / Sanfilippo B SBC-103 (rhNAGLU)
Slide 23: SBC-103 MPS IIIB / Sanfilippo B
© Copyright 2011 Synageva BioPharma™ 23 SBC-103 MPS IIIB / Sanfilippo B Heparan sulfate accumulation in CNS, liver, spleen, skin and joints May affect as many as 8 lives per million Progressive mental impairment with sleep disturbances and behavioral manifestations – Severe phenotype - wheelchair de
Slide 24: SBC-103 NAGLU Production for ERT
24 © Copyright 2011 Synageva BioPharma™ SBC-103 NAGLU Production for ERT Historical attempts to produce NAGLU ERT for MPS IIIB have failed due to lack of cell uptake Yogalingham G et al, 2000 NAG (nmol/h per mg) Normal fibroblasts 25.12 2.23 MPS-IIIB fibroblasts 0.101 0.025 MPS-IIIB fibroblasts + MP
Slide 25: Synageva Expression Platform
25 © Copyright 2011 Synageva BioPharma™ Synageva Expression Platform Proprietary Vector System Human Biopharmaceutical Expression in Egg White FDA-accepted Aseptic Protein Harvest GMP compliant facilities Automated commercial scale infrastructure Finished Product Stable commercial supply Consistent
Slide 26: SBC-102 Commercial: Ultra-Orphan Opportunity
Drug Indication Estimated Prevalence Reported 2010 Revenue ($M) 26 © Copyright 2011 Synageva BioPharma™ SBC-102 Commercial: Ultra-Orphan Opportunity SBC-102 Cerezyme Fabrazyme Myozyme Soliris SBC-103 LAL Deficiency Type I Gaucher Disease Fabry Disease Pompe Disease PNH MPS IIIB/ Sanfilippo B 1 in 40
Slide 27: SBC-102 Commercial: Finding Patients
© Copyright 2011 Synageva BioPharma™ 27 Right Practice Right Patient Right Test SBC-102 Commercial: Finding Patients ~17,000 homozygotes with LAL mutation ~17,000 homozygotes with LAL mutation Estimated distribution for US, EU and BR Estimated distribution for US, EU and BR Enzyme DNA Simple blood t
Slide 28: Commercial: Rare & Devastating Disease in a Common Phenotype
28 © Copyright 2011 Synageva BioPharma™ Commercial: Rare & Devastating Disease in a SBC-102 Common Phenotype 30-60M Americans have NAFLD 6-10M Americans have NASH http://www.digestive.niddk.nih.gov/ddiseases/pubs/NASH/ Muntoni, et al; “Prevalence of Cholesteryl Ester Storage Disease”, Arterioscleros
Slide 29: Synageva Value Drivers in Two Distinct Stages
Multiple Value Drivers Stage 1 Investing in the future Valued as a clinical stage biotech First-ever ERT for LAL in humans Stage 2 Commercial-stage biotech Potential Five product Valued on revenue and margin Synageva Value Drivers in Two Distinct Stages 29 © Copyright 2011 Synageva BioPharma™ Proof
Slide 30: Summary
30 © Copyright 2011 Synageva BioPharma™ Summary Financials Pro forma Synageva would have approximately $70 million in cash ending Q1 2011 Trimeris received $4.9 million upfront fee Trimeris to receive a 16% royalty on global sales of Fuzeon, an HIV drug marketed globally by Roche (55 countries) Cash
Slide 31: Synageva Pipeline of Opportunity
31 © Copyright 2011 Synageva BioPharma™ Synageva Pipeline of Opportunity Program Therapeutic Disease Development Status Regulatory Opportunity MULTIPLE VALUE DRIVING EVENTS SBC-102 (rhLAL) Recombinant Lysosomal Acid Lipase LAL Deficiency (LSD) Clinical Orphan Designation • Granted US • Granted EU Fa
Slide 32: Every Second Counts!
© Copyright 2011 Synageva BioPharma™ Every Second Counts! Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities of Trimeris or Synageva or the solicitation of any vote